{
  "_originalData": {
    "identity": {
      "bacteriumName": "Achromobacter xylosoxidans",
      "lastUpdated": "2024-04-29",
      "clsiCategory": "additional_bacteria",
      "classification": {
        "gramStain": "Gram negative",
        "morphology": "bacilli",
        "respiration": "glucose non-fermenter"
      },
      "strainDetails": [
        {
          "type": "Subspecies",
          "value": "Achromobacter xylosoxidans subspecies xylosoxidans",
          "notes": "the most common species clinically encountered. Fifteen species isolated from clinical specimens."
        }
      ],
      "biochemicalTests": "Gram-negative rod, oxidase +, catalase +, motile (peritrichous flagella), non-lactose fermenter, oxidizes xylose and glucose, citrate +, urease +."
    },
    "clinicalProfile": {
      "summary": "Found in soil and water. Cause of bacteremia, meningitis, catheter-related bloodstream infections, pneumonia, urinary tract infections, keratitis, and rarely from respiratory tract secretions from patients with cystic fibrosis.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Bacteremia"
        },
        {
          "syndromeName": "Meningitis"
        },
        {
          "syndromeName": "Catheter-related bloodstream infections"
        },
        {
          "syndromeName": "Pneumonia"
        },
        {
          "syndromeName": "Urinary tract infections"
        },
        {
          "syndromeName": "Keratitis"
        }
      ],
      "highRiskPopulations": [
        "Patients with cystic fibrosis"
      ]
    },
    "resistanceProfile": {
      "majorMechanisms": [
        {
          "mechanismName": "Multidrug efflux pumps"
        },
        {
          "mechanismName": "Chromosomal OXA-114-like beta-lactamases",
          "description": "Includes ESBLactamases, AmpC cephalosporinases, Carbapenemases to include metallo-beta-lactamases"
        }
      ],
      "intrinsicResistance": [
        {
          "drugOrClass": "Pen G, first & second generation cephalosporins, Ceftriaxone, Aztreonam, Tetracycline, aminoglycosides, azithromycin",
          "notes": "Wild type"
        },
        {
          "drugOrClass": "fluoroquinolones",
          "notes": "From cystic fibrosis patients"
        }
      ],
      "clinicalAlerts": [
        {
          "alertTitle": "Increasing Carbapenem Resistance",
          "details": "Increasing resistance to carbapenems secondary to activated efflux pumps and production of metallo-carbapenemases"
        },
        {
          "alertTitle": "High Fluoroquinolone Resistance",
          "details": "High frequency of fluoroquinolone resistance"
        }
      ]
    },
    "treatment": {
      "drugsToAvoid": [
        {
          "drugOrClass": "Doripenem",
          "condition": "Pneumonia"
        }
      ],
      "regimens": [
        {
          "context": {
            "type": "Directed",
            "patientPopulation": [
              "Non-cystic fibrosis patients"
            ]
          },
          "recommendations": [
            {
              "preference": "Primary",
              "drugs": [
                {
                  "drugName": "Cefepime",
                  "dose": "1-2 gm",
                  "route": "IV",
                  "frequency": "q8-12 h"
                },
                {
                  "drugName": "Ceftazidime",
                  "dose": "1-2 gm",
                  "route": "IV",
                  "frequency": "q8-12 h"
                },
                {
                  "drugName": "Imipenem-cilastatin",
                  "dose": "500 mg",
                  "route": "IV",
                  "frequency": "q6h"
                },
                {
                  "drugName": "Meropenem",
                  "dose": "1-2 gm",
                  "route": "IV",
                  "frequency": "q8h"
                },
                {
                  "drugName": "Doripenem",
                  "dose": "500 mg",
                  "route": "IV",
                  "frequency": "q8h"
                },
                {
                  "drugName": "Ciprofloxacin",
                  "dose": "400 mg",
                  "route": "IV",
                  "frequency": "q12h"
                },
                {
                  "drugName": "TMP/SMX",
                  "condition": "for UTIs"
                }
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Directed",
            "patientPopulation": [
              "Cystic fibrosis patients"
            ]
          },
          "recommendations": [
            {
              "preference": "Primary",
              "notes": [
                "There are no standard treatment protocols for cystic fibrosis pulmonary Achromobacter infections. Treatment usually consists of systemic and/or inhaled antibiotics",
                "Ceftazidime as above",
                "Carbapenem as above",
                "Inhaled antibiotics (ceftazidime, colistin and tobramycin). Controlled studies needed"
              ]
            }
          ]
        },
        {
          "context": {
            "type": "Salvage therapy"
          },
          "recommendations": [
            {
              "preference": "Alternative",
              "drugs": [
                {
                  "drugName": "Cefiderocol",
                  "dose": "2 gm",
                  "route": "IV",
                  "frequency": "over 3hr q8h"
                },
                {
                  "drugName": "Eravacycline",
                  "dose": "1 mg/kg",
                  "route": "IV",
                  "frequency": "q12h",
                  "comments": "not for UTIs"
                }
              ]
            }
          ]
        }
      ]
    },
    "additionalInformation": {
      "antimicrobialStewardship": [
        "Achromobacter are generally resistant to penicillin G, ceftriaxone, aztreonam, polymyxins and aminoglycosides."
      ],
      "guidelineReferences": [
        {
          "source": "Antimicrob Agents Chemother",
          "citation": "doi:10.1128/AAC.01025-20",
          "summaryOrNote": "Comprehensive review of treatment"
        },
        {
          "source": "Antimicrob Agents Chemother",
          "citation": "2020; 64: e01025"
        },
        {
          "source": "J Cyst Fibros",
          "citation": "2013: 12638"
        }
      ]
    }
  },
  "_metadata": {
    "originalKeys": [
      "identity",
      "clinicalProfile",
      "resistanceProfile",
      "treatment",
      "additionalInformation"
    ],
    "conversionTimestamp": "2025-07-15T03:16:49.359Z",
    "sourceFormat": "modern"
  },
  "identity": {
    "bacteriumName": {
      "sources": [
        "identity.bacteriumName"
      ],
      "value": "Achromobacter xylosoxidans"
    },
    "aliases": {
      "sources": [
        "identity.aliases",
        "aliases"
      ],
      "value": []
    },
    "lastUpdated": {
      "sources": [
        "identity.lastUpdated"
      ],
      "value": "2024-04-29"
    },
    "classification": {
      "sources": [
        "identity.classification"
      ],
      "value": {
        "gramStain": "Gram negative",
        "morphology": "bacilli",
        "respiration": "glucose non-fermenter"
      }
    }
  },
  "clinicalInformation": {
    "sources": [
      "clinicalProfile"
    ],
    "value": {
      "summary": "Found in soil and water. Cause of bacteremia, meningitis, catheter-related bloodstream infections, pneumonia, urinary tract infections, keratitis, and rarely from respiratory tract secretions from patients with cystic fibrosis.",
      "clinicalSyndromes": [
        {
          "syndromeName": "Bacteremia"
        },
        {
          "syndromeName": "Meningitis"
        },
        {
          "syndromeName": "Catheter-related bloodstream infections"
        },
        {
          "syndromeName": "Pneumonia"
        },
        {
          "syndromeName": "Urinary tract infections"
        },
        {
          "syndromeName": "Keratitis"
        }
      ],
      "highRiskPopulations": [
        "Patients with cystic fibrosis"
      ]
    }
  },
  "resistanceInformation": {
    "sources": [
      "resistanceProfile"
    ],
    "value": {
      "majorMechanisms": [
        {
          "mechanismName": "Multidrug efflux pumps"
        },
        {
          "mechanismName": "Chromosomal OXA-114-like beta-lactamases",
          "description": "Includes ESBLactamases, AmpC cephalosporinases, Carbapenemases to include metallo-beta-lactamases"
        }
      ],
      "intrinsicResistance": [
        {
          "drugOrClass": "Pen G, first & second generation cephalosporins, Ceftriaxone, Aztreonam, Tetracycline, aminoglycosides, azithromycin",
          "notes": "Wild type"
        },
        {
          "drugOrClass": "fluoroquinolones",
          "notes": "From cystic fibrosis patients"
        }
      ],
      "clinicalAlerts": [
        {
          "alertTitle": "Increasing Carbapenem Resistance",
          "details": "Increasing resistance to carbapenems secondary to activated efflux pumps and production of metallo-carbapenemases"
        },
        {
          "alertTitle": "High Fluoroquinolone Resistance",
          "details": "High frequency of fluoroquinolone resistance"
        }
      ]
    }
  },
  "treatmentData": {
    "treatmentData": {
      "_treatmentMetadata": {
        "originalFormat": "modern"
      },
      "standardizedRegimens": []
    }
  },
  "laboratoryData": {
    "sources": [
      "laboratoryProfile",
      "laboratory"
    ],
    "value": {}
  },
  "additionalData": {
    "antimicrobialStewardship": {
      "sources": [
        "antimicrobial_stewardship",
        "antimicrobialStewardship"
      ],
      "value": []
    },
    "comments": {
      "preservedStructure": {
        "originalFormat": "object"
      }
    },
    "diagnosis": {
      "sources": [
        "diagnosis"
      ],
      "value": []
    },
    "allOtherKeys": {}
  }
}